

Indexed in: PubMed



an Open Access Journal by MDPI

Vascular Malformation: From Pathophysiology, Clinical Manifestations to Novel Therapeutic Approaches

Guest Editors:

Dr. Hua Su

Center for Cerebrovascular Research, University of California, San Francisco, CA, USA

Dr. Li Ma

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Deadline for manuscript submissions:

31 July 2024

Message from the Guest Editors

Dear Colleagues,

Arteriovenous malformations (AVMs) are active angiogenic lesions consisting of tangles of abnormal vessels shunting blood directly from arteries to veins without a true capillary bed. The mechanism of AVM formation is not fully understood. Recent studies identified somatic mutations in genes in RAS-MAPK pathway in sporadic bAVMs and peripheral AVMs. However, the significance of these genes in AVM development needs to be studied further. The existing treatment modalities for AVM have considerable adverse effects. With the advance of imaging techniques, more asymptomatic AVM patients will be diagnosed. The asymptomatic patients has become treatment of increasingly controversial because the natural history of these patients may be less morbid than invasive therapy. Therefore, uncovering AVM pathogenesis and identifying targets for the development of specific medical therapies are urgently needed. This Special Issue focuses on the research topic of molecular mechanisms underlying AVM development and progression, clinical management, and targets for the development of new therapies. We welcome both original research and review manuscripts.







IMPACT FACTOR 4.7





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us